Aidence

Aidence is a Dutch startup founded in 2015, specializing in AI-powered clinical applications for the lung cancer pathway. The company's focus lies in using data to revolutionize disease prevention, management, and treatment. Aidence's Veye Lung Nodules solution, which is CE certified, is currently implemented in clinical practice and lung cancer screening across Europe. The company's last funding round, a €10.00M Series A investment on 20 February 2019, attracted notable investors including Northzone, henQ, Inkef, and Rabo Ventures. Aidence operates in the intersection of AI, Health Care, and Information Technology, standing out as part of the AI division of RadNet, a prominent US-based provider of diagnostic imaging services. The company's approach combines state-of-the-art technology with a mission to empower healthcare and pharmaceutical professionals, ultimately seeking to improve patient outcomes through faster and more precise diagnostics and treatments. Aidence is positioned for a scale-up challenge, evident in its open positions and the invitation to contribute to the creation of AI tools that will transform the healthcare industry. For those interested, a glimpse into Aidence's work culture can be found at http://bit.ly/lifeataidence, and job opportunities are available at https://www.aidence.com/join-the-team/.